YEARS 算法对比单纯 CTPA 诊断癌症患者疑似急性肺栓塞的随机对照试验方案(Hydra 研究)
Hydra 研究是一项研究者发起、多中心、多国、开放标签、随机、非劣效性试验,计划纳入 1566 例活动性癌症且临床疑似急性肺栓塞的患者,1:1 随机比较 YEARS 算法与单纯 CTPA 的诊断策略。主要安全性结局为初始排除肺栓塞者 3 个月内症状性且客观证实的致命或非致命 VTE 或无法排除急性肺栓塞为死因的死亡比例;主要效率结局为初始检查中 CTPA 阴性扫描占全部 CTPA 扫描的比例。
要点
- 癌症患者疑似肺栓塞时,YEARS 算法与单纯 CTPA 的诊断安全性和效率将被随机对照评估。
- 主要安全性结局为初始排除肺栓塞后 3 个月内症状性客观证实的 VTE 或无法排除肺栓塞为死因的死亡。
- 主要效率结局为初始检查中 CTPA 阴性扫描数占全部 CTPA 扫描数的比例。
核心结论
- 该研究方案旨在评估 YEARS 算法对比单纯 CTPA 在癌症疑似急性肺栓塞患者中的诊断安全性和效率,尚待试验结果验证。
研究设计与样本
- Hydra 研究(NCT04657120)为研究者发起、多中心、多国、开放标签、随机、非劣效性试验,采用结局事件盲法裁定。
- 计划纳入 1566 例活动性癌症、临床疑似急性肺栓塞、未接受治疗性抗凝或无肺栓塞以外抗凝指征的连续患者。
- 参与者通过基于网络的系统按 1:1 随机分配至 YEARS 算法组或单纯 CTPA 组。
关键数值与推荐
- 主要安全性结局为初始检查排除肺栓塞者 3 个月随访内症状性且客观证实的致命或非致命 VTE(肺栓塞或上肢/下肢深静脉血栓)或无法排除急性肺栓塞为 contributing factor 的死亡比例。
- 主要效率结局为初始检查中 CTPA 阴性扫描数相对于全部 CTPA 扫描数的比例。
临床怎么用
- 该方案针对癌症患者疑似急性肺栓塞的诊断管理,比较 YEARS 算法与单纯 CTPA 策略,结果为临床选择诊断路径提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thromb Res. 2026 Jul;263:109745. doi: 10.1016/j.thromres.2026.109745. Epub 2026 Jun 11. ABSTRACT BACKGROUND: Pulmonary embolism (PE) is frequently suspected in patients with cancer due to non-specific symptoms suggestive of PE and their inherent risk of venous thromboembolism (VTE). Commonly used clinical decision rules (CDRs) and D-dimer testing may be less reliable in this specific population. Due to the lack of guideline recommendations on the optimal diagnostic approach and the perceived futility of D-dimer in patients with cancer, clinicians often use computed tomography pulmonary angiography (CTPA) as a sole diagnostic test. This practice exposes patients to potentially unnecessary radiation and harm, and contributes to a significant burden on healthcare systems through inefficient resource allocation. The YEARS algorithm is an easy-to-use CDR that has been shown to safely exclude PE without the need for CTPA in a diverse population of patients with suspected PE. OBJECTIVE: To compare the safety and efficiency of the YEARS algorithm to the safety and efficiency of CTPA only in the diagnostic management of acute PE in cancer patients. DESIGN AND INTERVENTIONS: The Hydra study (ClinicalTrials.govNCT04657120) is an investigator-initiated, multicentre, multinational open-label, randomised, non-inferiority trial with blinded adjudication of outcome events, comparing the YEARS algorithm with CTPA only in the diagnostic work-up of cancer patients with clinically suspected acute PE. Participants are randomised in a 1:1 ratio to each diagnostic strategy via a web-based system. The trial anticipates to include 1566 patients. PARTICIPANTS: Consecutive patients with active cancer who are hospitalised or present to the emergency department, outpatient clinic, or thrombosis clinic with clinically suspected PE and who are not receiving therapeutic anticoagulation or have an indication for anticoagulation therapy other than PE. STUDY OUTCOMES: The primary safety outcome is the proportion of symptomatic and objectively proven fatal or non-fatal VTE (i.e., PE or deep vein thrombosis in the upper or lower extremities) or death with undetermined cause where acute PE could not be ruled out as contributing factor during three months follow-up in patients in whom PE was ruled out at initial testing. The primary efficiency outcome is the proportion of negative CTPA scans for PE, relative to the total number of CTPA scans performed at initial testing. IMPLICATION: This trial
引用
- PubMed 高证据 · 肺栓塞:A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。